Genentech, Syndax test atezolizumab/entinostat combo in triple-negative breast cancer
Syndax Pharmaceuticals Inc. agreed to test a combination of its histone deacetylase inhibitor entinostat with Genentech Inc.'s PD-L1 antagonist antibody atezolizumab (MPDL3280A).
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.